The main purpose of this work was to determine whether initiation of DPP-4 inhibitor linagliptin administration after onset of hypertension and cardiac hypertrophy can exert direct beneficial effects on cardiovascular injury induced by salt-sensitive hypertension. The gene discussed is DPP4; the disease is Hypertension.